To test this, we studied pretreatment and matched early-on-treatment BM immune signatures derived from next-generation sequencing (NGS) of the T cell receptor beta (TRB) repertoire in an AML cohort homogenously starting their systemic treatment with AZA within the RAS-AZIC study of the East German Study Group for Hematology and Oncology (OSHO)—an investigator-initiated multicenter trial combining AZA and standard chemotherapy in a sequential response-adapted design (OSHO #83; DRKS00004519) [32]. The gene discussed is THRB; the disease is acute myeloid leukemia.